Lungpacer
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Pennsylvania, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
260 Sierra Dr Ste 116, Exton, Pennsylvan...Phone Number
(484) 350-4530Website
www.lungpacer.comRevenue
$23.3 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Lungpacer
Lungpacer is a medical technology company focused on developing minimally invasive neurostimulation therapies that help critically ill patients regain independent breathing and reduce dependence on mechanical ventilation. The company specializes in diaphragm pacing and respiratory support technologies designed to strengthen the diaphragm, improve ventilator weaning outcomes, and support recovery in intensive care settings. Through its AeroPace system and ongoing clinical innovation, Lungpacer aims to transform respiratory and critical care by combining advanced neurostimulation technology with patient-centered therapeutic solutions for hospitals and healthcare providers worldwide.Explore more
Lungpacer Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lungpacer your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Lungpacer is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Lungpacer has new funding data
Check if Lungpacer has recently received funding, and reach out quickly before it becomes old news!
Click to see if Lungpacer had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Lungpacer
Lungpacer, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Lungpacer recently announced quarterly report
Product Launch: Get notified when Lungpacer launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Lungpacer
Compare insights from companies similar to Lungpacer, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Lungpacer is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lungpacer is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lungpacer.
Lungpacer financials insights
Gather financial insights about Lungpacer, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$19.6M
2021
Unspecified
$16M
2023
Series B
$20M
2026
Debt
$12M
Lungpacer Tech Stack
A closer look at the technologies used by Lungpacer
Most Recent Scoops
Open Position
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Executive Move
Executive Moves, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
Lungpacer News & Media
Lungpacer Announces Health Economic Analysis Demonstrating Clinical and Cost Benefits of AeroPace in Mechanically Ventilated Patients
Lungpacer Medical today announced results from a new health economic analysis demonstrating national average cost savings of ~$24,000 per episode.Lungpacer Announces New Category III CPT® Codes for AeroPace® Diaphragm Neurostimulation Therapy
New Category III CPT® Codes for the AeroPace® Diaphragm Neurostimulation Therapy support the development of future reimbursement pathwaysLungpacer Medical Announces Presentation of DONATE Data Reporting an Increase in Availability of Donor Lungs
Data shows transvenous phrenic nerve stimulation reduces lung collapse and significantly increases availability of lungs that meet transplant criteriaLungpacer Medical Appoints Steven Pfanstiel as Chief Financial Officer
Lungpacer Medical appoints Steven Pfanstiel as Chief Financial Officer to accelerate commercialization of FDA-approved AeroPace® System.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lungpacer
Sign Up For FreeTo access detailed company insights
Lungpacer is a medical technology company focused on developing minimally invasive neurostimulation therapies that help critically ill patients regain independent breathing and reduce dependence on mechanical ventilation. The company specializes in diaphragm pacing and respiratory support technologies designed to strengthen the diaphragm, improve v... Read More
